NCT06574620 Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
| NCT ID | NCT06574620 |
| Status | Recruiting |
| Phase | — |
| Sponsor | British Columbia Cancer Agency |
| Condition | Pancreatic Ductal Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-11-28 |
| Primary Completion | 2028-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria prior to Pre-Baseline registration: 1. Age 18 years or older. 2. Histological or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC. 3. Medically fit and planned to undergo laparoscopic procedure as part of standard of care. 4. Able to give informed consent for the study-related procedures performed during laparoscopy. Participants must meet all of the following criteria to be eligible for enrollment in the Main Study: 1. Age 18 years or older. 2. Enrolled in the Personalized Oncogenomics (POG) Program at BC Cancer. 3. Histological and/or radiological diagnosis of resectable, borderline resectable, or locally advanced PDAC. Participants without a histological diagnosis of PDAC must undergo confirmatory histological diagnosis prior to treatment start date. 4. Medically fit to undergo surgical resection of the primary lesion(s) as judged by the investigator (Resectable and Borderli